Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Hormone. Mayo Clinic and Mayo Foundation, Rochester, MN, United States

Survival: 20.2 months
Toxicity Grade: 3
Treatments: Hormone
Country: United States
City/State/Province: Rochester, MN
Hospital: Mayo Clinic and Mayo Foundation
Journal: Link
Date: 3/2006

Patients: This phase II study involved 77 patients (median age 68) with advanced breast cancer who experienced disease progression after treatment with a third generation aromatase inhibitor and at most, one adiditional hormone agent. The tumors were estrogen receptor and/or progesterone receptor positive.

Treatment: The treatment consisted of hormone therapy (the anti-estrogen drug Fulvestrant).

Toxicity: Grade 3 toxicitites included fatigue, bone pain, and dyspnea.

Results: Median overall survival was 20.2 months.

Support: One of the authors has acted as a consulted for Astra Zeneca and another has received research funds from Astra Zeneca. Astra Zeneca manufactures and/or markets Fulvestrant.

Corresepondence: Dr. James N. Ingle

E-mail to a Friend Email Physician More Information